NVO vs PRTA
NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access. PRTA: A clinical-stage biotech developing antibody therapies targeting misfolded proteins in Parkinson's disease, Alzheimer's disease, and rare amyloidosis through proprietary CYTOPE® intracellular delivery technology, in partnership with major pharma.
Side-by-side fundamentals
| Metric | NVO | PRTA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $48.19 | $8.44 | |
| Market cap as of 2026-07-23 | $219.8B | $458M | |
| P/E as of 2026-07-23 | 11.78 | n/a | |
| PEG as of 2026-07-23 | 16.16 | -0.09 | PRTA lower |
| Net margin as of 2026-07-23 | +37.2% | -260.9% | NVO higher |
| Gross margin as of 2026-07-23 | +81.8% | n/a | |
| Operating margin as of 2026-07-23 | +45.3% | -205.4% | NVO higher |
| ROE as of 2026-07-23 | +66.4% | -49.9% | NVO higher |
| ROA as of 2026-07-23 | +23.3% | -42.3% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.00 | PRTA lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.1% | -58.0% | NVO higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -43.6% | |
| Dividend yield as of 2026-07-23 | +3.7% | n/a | |
| Beta as of 2026-07-23 | 1.85 | -0.38 | |
| 1-year return as of 2026-07-22 close | -23.8% | +29.2% | PRTA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.